Incyte’s Jakafi Gets Additional Claim Based On Patient-Reported Outcomes

Jakafi is the first approved treatment for myelofibrosis, a rare bone marrow cancer, but Incyte will also be able to claim efficacy against the symptoms of the disease thanks to data in labeling from a patient-reported outcomes tool.